Pan Zehong – Trademark Portfolio

Entity Type: 01

Pan Zehong holds 8 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 5 filings in this category. The portfolio also extends into Class 16 (Paper Goods) across 3 Nice Classification classes. Currently, 1 trademark is registered and 5 are pending. Notable registered marks include HXDZA. The owner is based in Guangzhou.

Yunyuan Third Street, Baiyun District,

One of the public collectives, No. 31,

Guangzhou 510405 , CN

8 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

Pan Zehong's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (5 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

16
Paper Goods (2 filings)

Paper and cardboard; printed matter; bookbinding material; photographs; stationery

12
Vehicles (1 filing)

Vehicles; apparatus for locomotion by land, air or water

Frequently Asked Questions

How many trademarks does Pan Zehong have?

Pan Zehong has 8 U.S. trademarks filed with the USPTO. Of these, 1 registered, 5 pending.

What trademark classes does Pan Zehong file in?

Pan Zehong files trademarks across 3 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 16 (Paper Goods), Class 12 (Vehicles). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are Pan Zehong's most well-known trademarks?

Pan Zehong's registered trademark portfolio includes well-known marks such as HXDZA. These are among 1 currently registered trademark in the portfolio.

What is Pan Zehong's trademark registration success rate?

Pan Zehong has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 5 applications are pending review.